Most people have a relative, friend or neighbor who has had to deal with a cataract. Nearly 24.5 million Americans age 40 or older are affected by cataracts, and it’s the leading cause of blindness ...

The Conversation reports cataract surgery is safe and common, with over 90% achieving 20/20 vision, but patients need to ...

Primary IOL implantation in pediatric open globe injuries with active inflammation showed inferior visual outcomes compared ...

The Tecnis PureSee IOL is the first FDA-approved extended depth of focus IOL maintaining contrast sensitivity comparable to ...

Johnson & Johnson (NYSE:JNJ) received FDA approval for its TECNIS PureSee IOL, an extended depth of focus intraocular lens for cataract patients. The lens is described as the first of its kind in the ...

Cataract surgery remains one of the most frequently performed and successful surgical procedures worldwide, involving the removal of a clouded natural lens and its replacement with an intraocular lens ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

Among children who underwent unilateral cataract removal in infancy, risk of glaucoma-related adverse events continues to increase with longer follow-up and is not associated with primary intraocular ...

In response to this education gap, Eye Surgery Today was founded by nationally recognized key opinion leaders (KOLs) to make high-quality eye surgery education accessible to everyone.

Johnson & Johnson (JNJ) wins FDA approval for Tecnis PureSee intraocular lens ((IOL)), giving eye surgeons a new lens option for use in cataract surgery. Read more here.